Literature DB >> 31575669

The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.

Anna Orlova1, Heidi A Neubauer1, Richard Moriggl1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31575669      PMCID： PMC6886418          DOI： 10.3324/haematol.2019.225862

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Authors:  Amanda Kirane; Kathleen F Ludwig; Noah Sorrelle; Gry Haaland; Tone Sandal; Renate Ranaweera; Jason E Toombs; Miao Wang; Sean P Dineen; David Micklem; Michael T Dellinger; James B Lorens; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-07-23       Impact factor: 12.701

Review 2.  Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies.

Authors:  Robert L Bowman; Lambert Busque; Ross L Levine
Journal:  Cell Stem Cell       Date:  2018-02-01       Impact factor: 24.633

Review 3.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

4.  FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.

Authors:  Ayako Nogami; Gaku Oshikawa; Keigo Okada; Shusaku Fukutake; Yoshihiro Umezawa; Toshikage Nagao; Tetsuya Kurosu; Osamu Miura
Journal:  Oncotarget       Date:  2015-04-20

Review 5.  The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy.

Authors:  Magdalena Paolino; Josef M Penninger
Journal:  Cancers (Basel)       Date:  2016-10-21       Impact factor: 6.639

Review 6.  Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics.

Authors:  Elisa Holstein; Mathias Binder; Wolfgang Mikulits
Journal:  Int J Mol Sci       Date:  2018-12-18       Impact factor: 5.923

Review 7.  Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Authors:  Naval Daver; Richard F Schlenk; Nigel H Russell; Mark J Levis
Journal:  Leukemia       Date:  2019-01-16       Impact factor: 11.528

8.  Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Authors:  Takahiro Yoshioka; Kazuhiko Shien; Tatsuaki Takeda; Yuta Takahashi; Eisuke Kurihara; Yusuke Ogoshi; Kei Namba; Hidejiro Torigoe; Hiroki Sato; Shuta Tomida; Hiromasa Yamamoto; Junichi Soh; Toshiyoshi Fujiwara; Shinichi Toyooka
Journal:  Cancer Sci       Date:  2019-06-24       Impact factor: 6.716

9.  High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.

Authors:  Barbara Maurer; Harini Nivarthi; Bettina Wingelhofer; Ha Thi Thanh Pham; Michaela Schlederer; Tobias Suske; Reinhard Grausenburger; Ana-Iris Schiefer; Michaela Prchal-Murphy; Doris Chen; Susanne Winkler; Olaf Merkel; Christoph Kornauth; Maximilian Hofbauer; Birgit Hochgatterer; Gregor Hoermann; Andrea Hoelbl-Kovacic; Jana Prochazkova; Cosimo Lobello; Abbarna A Cumaraswamy; Johanna Latzka; Melitta Kitzwögerer; Andreas Chott; Andrea Janikova; Šárka Pospíšilova; Joanna I Loizou; Stefan Kubicek; Peter Valent; Thomas Kolbe; Florian Grebien; Lukas Kenner; Patrick T Gunning; Robert Kralovics; Marco Herling; Mathias Müller; Thomas Rülicke; Veronika Sexl; Richard Moriggl
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

10.  Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Authors:  Bettina Wingelhofer; Barbara Maurer; Elizabeth C Heyes; Abbarna A Cumaraswamy; Angelika Berger-Becvar; Elvin D de Araujo; Anna Orlova; Patricia Freund; Frank Ruge; Jisung Park; Gary Tin; Siawash Ahmar; Charles-Hugues Lardeau; Irina Sadovnik; Dávid Bajusz; György Miklós Keserű; Florian Grebien; Stefan Kubicek; Peter Valent; Patrick T Gunning; Richard Moriggl
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528
View more
  4 in total

Review 1.  From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia.

Authors:  Carmelo Gurnari; Maria Teresa Voso; Jaroslaw P Maciejewski; Valeria Visconte
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

2.  Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition.

Authors:  Kran Suknuntha; Yoon Jung Choi; Ho Sun Jung; Aditi Majumder; Sujal Shah; Igor Slukvin; Erik A Ranheim
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

Review 3.  A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation.

Authors:  Marta Surbek; William Tse; Richard Moriggl; Xiaonan Han
Journal:  Cytokine       Date:  2021-01-19       Impact factor: 3.861

4.  Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia.

Authors:  Javier Bregante; Anna Schönbichler; Daniel Pölöske; Lina Degenfeld-Schonburg; Garazi Monzó Contreras; Emir Hadzijusufovic; Elvin D de Araujo; Peter Valent; Richard Moriggl; Anna Orlova
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.